Bicycle Therapeutics plc (NASDAQ:BCYC) Shares Sold by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC decreased its holdings in Bicycle Therapeutics plc (NASDAQ:BCYC) by 76.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,328 shares of the company’s stock after selling 7,539 shares during the period. Tower Research Capital LLC TRC’s holdings in Bicycle Therapeutics were worth $42,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the business. Armistice Capital LLC lifted its position in shares of Bicycle Therapeutics by 53.6% during the 4th quarter. Armistice Capital LLC now owns 1,536,000 shares of the company’s stock worth $27,771,000 after purchasing an additional 536,000 shares during the last quarter. Westfield Capital Management Co. LP acquired a new position in Bicycle Therapeutics in the fourth quarter valued at $16,585,000. Trexquant Investment LP increased its stake in Bicycle Therapeutics by 177.6% in the fourth quarter. Trexquant Investment LP now owns 196,323 shares of the company’s stock valued at $3,550,000 after purchasing an additional 125,604 shares during the period. Jump Financial LLC increased its stake in Bicycle Therapeutics by 108.6% in the fourth quarter. Jump Financial LLC now owns 77,332 shares of the company’s stock valued at $1,398,000 after purchasing an additional 40,265 shares during the period. Finally, BNP Paribas Financial Markets increased its stake in Bicycle Therapeutics by 10,489.4% in the fourth quarter. BNP Paribas Financial Markets now owns 36,851 shares of the company’s stock valued at $666,000 after purchasing an additional 36,503 shares during the period. Institutional investors and hedge funds own 86.15% of the company’s stock.

Bicycle Therapeutics Trading Up 2.0 %

Shares of BCYC traded up $0.49 on Thursday, hitting $24.69. 606,373 shares of the stock traded hands, compared to its average volume of 374,303. The company has a quick ratio of 8.08, a current ratio of 8.08 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $741.69 million, a P/E ratio of -4.81 and a beta of 0.90. The stock’s 50 day moving average is $24.01 and its two-hundred day moving average is $19.40. Bicycle Therapeutics plc has a 1 year low of $12.54 and a 1 year high of $28.91.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings data on Tuesday, February 20th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.23) by $0.07. The business had revenue of $5.33 million for the quarter, compared to the consensus estimate of $11.68 million. Bicycle Therapeutics had a negative net margin of 669.72% and a negative return on equity of 57.80%. As a group, sell-side analysts predict that Bicycle Therapeutics plc will post -5.2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. HC Wainwright dropped their price target on shares of Bicycle Therapeutics from $57.00 to $55.00 and set a “buy” rating on the stock in a research note on Wednesday, February 21st. Canaccord Genuity Group restated a “buy” rating and set a $60.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday, February 21st. Finally, Needham & Company LLC restated a “buy” rating and set a $43.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday, April 10th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Bicycle Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.86.

Insider Activity at Bicycle Therapeutics

In related news, CEO Kevin Lee sold 3,158 shares of the company’s stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $23.81, for a total transaction of $75,191.98. Following the transaction, the chief executive officer now owns 387,270 shares of the company’s stock, valued at $9,220,898.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Over the last 90 days, insiders have sold 5,312 shares of company stock valued at $126,139. Company insiders own 10.20% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.